pharmaphorum

NOVEMBER 18, 2022

The US regulator has approved the anti-CD3 antibody as Tzield to delay the onset of stage 3 T1D in people eight years and older who currently have stage 2 disease, which according to the FDA “may provide patients with months to years without the burdens of disease.”

Drugs 52

Drugs FDA Approval Insulin Clinical Trials 52

pharmaphorum

DECEMBER 18, 2020

Originally approved in 2011 as an IV therapy for adults with SLE, a debilitating autoimmune disease, GSK got a green light for the subcutaneous formulation in 2017 and last year extended the label of the antibody to include paediatric patients aged over five.

FDA Approval 100

FDA Approval Contract Manufacturing Sales Trials 100

pharmaphorum

MARCH 21, 2022

Prior to the FDA rejection , GlobalData was predicting global peak sales of $691 million for teplizumab in 2027. Provention is seeking approval of teplizumab as a treatment to delay clinical type 1 diabetes in at-risk individuals, hoping the drug can become the first disease-modifying therapy in these patients.

Drugs 52

Drugs Insulin Contract Manufacturing Clinical Trials 52

XTalks

APRIL 11, 2024

On the other hand, Abecma is now approved as a third-line treatment for patients with triple-class-exposed disease, which means previous treatment with an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody. Plasma cells help fight infections by producing antibodies.

FDA Approval 52

FDA Approval Manufacturing Trials Clinical Trials 52

The Pharma Data

NOVEMBER 5, 2020

net sales increased 11% to $1.32 Third quarter 2020 Dupixent ® global net sales (2) , which are recorded by Sanofi, increased 69% to $1.07 “This is evidenced by Dupixent achieving in excess of $1 billion in global net sales this quarter.” REGN-COV2 , a dual antibody therapy to SARS-CoV-2 virus.

Sales 52

Sales Production Manufacturing Antibody 52

The Pharma Data

JULY 29, 2021

Following the completion of the spin-off of the Upjohn Business(6) in the fourth quarter of 2020, Pfizer operates as a focused innovative biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products worldwide. Revenues $78.0 billion (previously $70.5

Manufacturing 52

Manufacturing Sales Contract Manufacturing Vaccination 52

The Pharma Data

DECEMBER 23, 2020

Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” mg dose group and 84% demonstrating neutralizing antibodies in the 2.0 mg and 2.0 The 1.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

Pharmaceutical Technology

APRIL 24, 2023

These attributes make some biologic drugs, especially monoclonal antibodies more specific and targeted in their treatment. The recent pandemic has highlighted severe shortcomings with respect to the availability of contract manufacturing facilities,” says Bhalgat.

Contract Manufacturing 130

Contract Manufacturing Manufacturing Protein Sales 130

The Pharma Data

MAY 4, 2021

Following the completion of the spin-off of the Upjohn Business (4) in the fourth quarter of 2020, Pfizer now operates as a focused innovative biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sales and distribution of biopharmaceutical products worldwide. previously $59.4 previously 32.0%

Vaccination 40

Vaccination Vaccine Production Sales 40